Visiting The Royal Marsden is suspended

Coronavirus latest: Please kindly note that whilst lockdown restrictions are beginning to ease, visiting is still suspended.  The hospital remains open and we are still delivering treatment to our patients. Please see more information here about how we are keeping everyone safe.

Haemato-oncology clinical trials

Clinical trials are an important part of improving treatment for patients.

Acute leukaemias

Acute myeloid leukaemia (AML) trials

  • Trial of dual aurora kinase, FLT3 inhibitor for adults with AML relapsed or refractory to conventional therapy.
  • Trial of MDM2 antagonist in combination with low intensity chemotherapy for relapsed/refractory AML with wild type TP53 in adults
  • AML19 for untreated patients aged 18-60 years with AML. Looking at the combination of gemtuzumab ozogamicin and midostaurin in combination with standard chemotherapy
  • AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy

Acute lymphoblastic leukaemia (ALL) trials

  • MEK inhibitor trial for relapsed/refractory acute lymphoblastic leukaemia with RAS-pathway mutations in adults.
  • Daratumumab plus chemotherapy for first relapsed/refractory T acute lymphoblastic leukaemia in young adults (<30 years)

Chronic lymphoid leukaemias

  • Randomised clinical trial comparing R-FC to R-Ibrutinib in treatment naïve CLL patients with intact TP53
  • Randomised clinical trial comparing Ibrutinib to Acalabrutinib in patients with previously treated CLL with ATM or TP53 loss

Lymphoma

  • A dose-finding study of single agent idelalisib in the treatment of double-refractory follicular lymphoma
  • A clinical trial of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory DL

Myelodysplastic syndromes and other myeloid disorders

For patients with low blood counts of uncertain cause we have a gene sequencing study to test whether any genes are mutated.

 

Academic and commercial trials are run through the Haemato-oncology Unit. Trials that are currently recruiting are listed below under each disease category.

Please email us for more information about our haemato-oncology clinical trials.